Preventing hepatic MF activation by targeting the LPS–TLR4 axis may thus represent a valid therapeutic strategy for CLD, especially since pharmacological inhibition of TLR4 has already been shown to ameliorate liver injury and inflammation in experimental fibrosis/cirrhosis [130,134]. This evidence concerns the gene TLR4 and congenital secretory chloride diarrhea 1.